Türk Medline
ADR Yönetimi
ADR Yönetimi

PREDICTIVE FACTORS OF BK VIRUS DEVELOPMENT IN KIDNEY TRANSPLANT RECIPIENTS AND THE EFFECT OF LOW-DOSE TACROLIMUS PLUS EVEROLIMUS ON CLINICAL OUTCOMES

VURAL TANER YİLMAZ, ABDULLAH KİSAOGLU, ALİ AVANAZ, OZGUR DANDİN, DENİZ OZEL, ISMAİL DEMİRYİLMAZ, DERYA MUTLU, BAHAR AKKAYA, BULENT AYDİNLİ, HUSEYİN KOCAK

Experimental and Clinical Transplantation - 2023;21(9):727-734

Department of Internal Medicine, Division of Nephrology, Akdeniz University Medical School, Antalya, Turkey

 

Objectives: This study aimed to determine the predictive factors of BK virus viremia/nephropathy in kidney transplant recipients and to evaluate the effects of low-dose tacrolimus plus everolimus. Materials and Methods: This study included 3654 kidney transplant recipients. The patients were divided into 2 groups: group 1 were BK virus negative (n = 3525, 96.5%) and group 2 were BK virus positive (n = 129, viremia 3.5%, nephropathy 1%). Predictive factors were determined by receiver operating characteristic curve analysis and logistic regression models. We also divided and analyzed patients with BK virus viremia/nephropathy into 2 groups according to immunosuppressive changes. Group 2a had been switched to low-dose tacrolimus plus everolimus (n = 54, 41.9%), and group 2b had been switched to other immunosuppressive protocols (n = 75, 58.1%). Results: We found that use of anti-T-cell lymphocyte globulin and tacrolimus, deceased donor transplant, and rejection were predictive factors for BK virus viremia/nephropathy. In addition, patients who had low-dose calcineurin inhibitor plus mammalian target of rapamycin inhibitor regimens showed a low rate of BK virus development (only 6.2% of all cases). In Group 2a, both the BK polyomavirus-associated nephropathy rate (n = 23 [42.6%] vs n = 12 [16%] in group 2b; P = .001) and viral load (DNA > 104 copies/mL) (n = 49 [90.7%] vs n = 27 [36%] in group 2b; P = .001) were increased versus group 2b. Graft function, graft survival, viral clearance, and rejection rate were similar between the groups after protocol change. Conclusions: BK virus viremia/nephropathy rate was lower in patients who received low-dose calcineurin inhibitor plus mammalian target of rapamycin inhibitor protocols; the low-dose tacrolimus plus everolimus switch protocol after BK virus was more effective and safe than other protocols.